|Source||Chimeric/humanized hybrid (mouse/human)|
|Chemical and physical data|
|Molar mass||148251.25 g·mol−1|
Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme. It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors. Phase I results were presented at ASCO in 2016.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.
- World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- "Antibody-drug conjugates in the spotlight - The Antibody Society". antibodysociety.org. 14 October 2016.
- Nagayama A, Ellisen LW, Chabner B, Bardia A (December 2017). "Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments". Targeted Oncology. 12 (6): 719–739. doi:10.1007/s11523-017-0535-0. PMID 29116596. S2CID 1012740.
- "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019". abbvie.com. Retrieved 20 May 2019.
- "Depatuxizumab mafodotin". en.pharmacodia.com.
- "Depatuxizumab mafodotin - AbbVie - AdisInsight". adisinsight.springer.com.